InspireMD (NYSE:NSPR) Shares Down 1.5% – Time to Sell?

InspireMD, Inc. (NYSE:NSPR – Get Free Report)’s stock price dropped 1.5% on Monday. The stock traded as low as $0.67 and last traded at $0.6895. Approximately 23,494 shares were traded during trading, a decline of 83% from the average daily volume of 141,243 shares. The stock had previously closed at $0.70.

InspireMD Price Performance

The company has a market cap of $32.05 million, a price-to-earnings ratio of -0.92 and a beta of 0.83. The business’s 50-day simple moving average is $0.79 and its 200-day simple moving average is $1.00.

Institutional Investors Weigh In On InspireMD

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC purchased a new position in InspireMD during the second quarter worth $2,363,876. Parkman Healthcare Partners LLC purchased a new stake in shares of InspireMD in the second quarter valued at $1,692,000. BlackRock Inc. acquired a new stake in shares of InspireMD during the second quarter valued at $86,000. Finally, Renaissance Technologies LLC purchased a new stake in InspireMD during the 1st quarter worth about $29,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

(Get Free Report)

InspireMD, Inc (NYSE:NSPR) is a medical device company focused on developing and commercializing products for the treatment of vascular disease. The company’s primary focus is carotid artery disease, a condition in which plaque buildup can restrict blood flow and increase the risk of stroke.

Its principal product is the CGuard Embolic Prevention System (EPS), a carotid stent system that combines a self-expanding stent with a fine mesh layer called MicroNet. The design is intended to stabilize plaque, reduce plaque protrusion through the stent, and help limit the release of embolic material during and after carotid artery procedures.

Featured Stories

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.